Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monthly intravenous C.E.R.A. versus intravenous epoetin alfa for maintenance of hemoglobin in hemodialysis patients with chronic renal anemia
2007-002065-12Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Uraemic Anaemia comparing Monthly intravenous Mircera with Intravenous epoetin alfa control (2 arms). Primary endpoints: Primary efficacy evaluation period, Long-term maintenance of hemoglobin concentration and 1 more. Started Jul 2007; status: completed.
02
Drugs
Epoetin alfa RBepoetin alfa
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on 2007-002065-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002065-12.